Clinical Trials Logo

Carcinoma in Situ clinical trials

View clinical trials related to Carcinoma in Situ.

Filter by:

NCT ID: NCT06327568 Recruiting - Anal Cancer Clinical Trials

Anal Cancer and/or Precancer Screening: Performance Analysis of the BD Onclarity™ HPV Assay on Anal Specimens

Start date: June 17, 2022
Phase:
Study type: Observational

Human papillomavirus (HPV) infection has been implicated as a necessary cause for the development of the majority of anogenital neoplasms which represent approximately 95% of anal tumors. Persistent high risk HR-HPV infection promotes progression from intraepithelial lesions high-grade squamous anal tumors (AIN) (H-SIL) to invasive anal tumors. The diagnosis of AIN is made by cytology or biopsy during routine examinations. To date, no HPV test has been clinically validated for anal specimens and none are available in the molecular diagnostics market for this purpose. The performance analysis of an HPV Test with simultaneous genotyping on anal samples could implement anal cancer screening without an invasive procedure and with one simple approach.

NCT ID: NCT06325592 Completed - Clinical trials for High-Grade Squamous Intraepithelial Lesions

Association Between Surgical Timing and Route of Total Hysterectomy After LEEP and Perioperative Risk in Patients With Cervical HSIL

Start date: October 1, 2023
Phase:
Study type: Observational

This study aimed to analyze perioperative information in patients with high-grade squamous intraepithelial lesion (HSIL) undergoing total hysterectomy (TH), offering insights into optimal surgery timing, selecting the operation path, and enhancing surgical operation details.

NCT ID: NCT06324825 Recruiting - Clinical trials for Atrophic Gastritis With Low-grade Intraepithelial Neoplasia

Fuzheng Nizeng Formula for Chronic Atrophic Gastritis With Low-grade Intraepithelial Neoplasia, a Multicenter Randomized Controlled Trial

Start date: October 24, 2022
Phase: N/A
Study type: Interventional

Fuzheng Nizeng Formula (FZNZ) is derived from the classic formula Liujunzi Decoction. Former pilot study found that FZNZ promoted the recovery of gastric atrophy and relieve the relative symptoms. This study is to evaluate its efficacy for chronic atrophic gastritis with low-grade intraepithelial neoplasia, compared with positive control Molduodan granule.

NCT ID: NCT06310369 Not yet recruiting - Bladder Cancer Clinical Trials

Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer

Start date: March 1, 2025
Phase: Phase 2
Study type: Interventional

We aim to investigate a possible role for radiotherapy in good prognosis bladder cancer patients has been identified as a possible alternative to cystectomy, especially for patients non-eligible for surgery but has yet to be fully explored.

NCT ID: NCT06297187 Active, not recruiting - Clinical trials for Condylomata Acuminata

Cavitronic Ultrasonic Surgical Aspiration (CUSA) Women's Health Study

Start date: February 23, 2024
Phase:
Study type: Observational

The study is a single arm, retrospective, single-center, post market registry. The purpose of this Registry is to collect data to demonstrate the safety and performance of CUSA® for the treatment of Vulvar Intraepithelial Neoplasia (VIN) and condyloma acuminata.

NCT ID: NCT06276101 Recruiting - Clinical trials for High-grade Squamous Intraepithelial Lesion (HSIL)

NWRD08 DNA Plasmid for HPV-16 and/or HPV-18 Related Cervical HSIL

Start date: January 25, 2024
Phase: Phase 1
Study type: Interventional

This is a single-arm, open label, multi-center Phase 1 clinical study to evaluate the safety and tolerability of HPV-16 and HPV-18-targeted DNA plasmid vaccine (NWRD08) in patients HPV-16 and/or HPV-18 related cervical HSIL.

NCT ID: NCT06273553 Not yet recruiting - Clinical trials for Cervical Intraepithelial Neoplasia Grade 2/3

A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3

Start date: March 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to to evaluate the safety, tolerability, immunogenicity, and efficacy of RG002 Injection in subjects with HPV16/18 associated Cervical Intraepithelial Neoplasia Grade 2 or 3(CIN2/3).

NCT ID: NCT06263582 Not yet recruiting - Cervix Cancer Clinical Trials

Pharmacokinetics of Intravaginal, Self-administered Artesunate Vaginal Pessaries Among Women in Kenya

Start date: June 2024
Phase: Phase 1
Study type: Interventional

This study investigates the pharmacokinetics of Artesunate (AS) and dihydroartemisinin (DHA), the active metabolite of Artesunate, following intravaginal use at the dosing and frequency being studied for cervical precancer treatment. A secondary objective is to investigate safety among study participants.

NCT ID: NCT06258564 Not yet recruiting - Recurrence Clinical Trials

The Adjuvant Effect of HPV Vaccination on Recurrence of Cervical Precancer or Carcinoma in Women Undergoing Conization

Start date: May 1, 2024
Phase:
Study type: Observational

Assessment of the association between human papillomavirus vaccination (HPV) and recurrences of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) in women undergoing conization.

NCT ID: NCT06234488 Active, not recruiting - Breast Cancer Clinical Trials

Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study

Start date: December 8, 2023
Phase:
Study type: Observational

There is no granular retrospective data on breast cancer in transgender and gender-diverse (TGD) persons from a contemporary and diverse American cohort. The purpose of this investigation is to aggregate data from multiple institutions to describe the risk, diagnosis, management, and outcomes of TGD persons with breast cancer in effort to identify opportunities for future intervention studies to eliminate breast cancer disparities for this population.